Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious, and other diseases.

 
 
 
 

Event Details


Sarepta Corporate Update on Accelerated Approval of EXONDYS 51TM Conference Call
Monday, September 19, 2016 4:00 p.m. ET  
Webcast Presentation
Click here for webcast
Add to Calendar Help
Add to Calendar Click here to add this event to your calendar

Event Details
TitleSarepta Corporate Update on Accelerated Approval of EXONDYS 51TM Conference Call
Date and TimeMonday, September 19, 2016 4:00 p.m. ET  
Description

The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 international callers. The passcode for the call is 85217990. Please specify to the operator that you would like to join the "Sarepta Corporate Update".

Forward Looking Statement
We will be making a number of forward-looking statements on this call which involve certain assumptions, risks and uncertainties.  These forward-looking statements include Exondys 51's benefits and mechanism of action, the potential market size for Exondys 51, our launch readiness, our mission in DMD, and our pipeline plans and the next planned regulatory filing for Exondys51, our commitment to help appropriate patients access Exondys51, the expected average annual cost of Exondys51, potential plans for our rare pediatric disease priority review voucher, our key priorities aimed at supporting a successful launch of Exondys 51, our patient support program plans for patient access to therapy, our commercial and supply chain readiness, our plans for our confirmatory Exondys51 trials to verify clinical benefit, our plans to work with the FDA on Company goals including speeding and shaping the development and approval of follow-on and rare exons.

Actual results could materially differ from these forward-looking statements and any applicable risks and uncertainties can materially and adversely affect our business, results of operations, and the trading price. For a detailed description of risks and uncertainties we face, you're encouraged to review the Company's latest 10-K and 10-Q and other official corporate documents filed with the Securities and Exchange Commission. Any forward-looking statements apply only as of today's date and we undertake no duty to update any of these statements after this call.